Abstract

Objective: Mucronulatol is one of the most cytotoxic substances present in Caribbean propolis. This work aimed at initially characterizing the biological effects of mucronulatol in cancer cell lines comprehending both wildtype and resistant sublines. Materials and methods: An RP-HPLC technique was employed to separate and purify mucronulatol. IC50 values were determined using the sulforhodamine B (SRB) proliferation assay. FACS-based cell cycle studies were carried out combining propidium iodide staining and 5-bromo-2’-deoxyuridine incorporation. Cell cycle regulator proteins were detected by Western blotting. The transcription of genes of interest was analyzed using RT-PCR. Results: In MDR1–/MDR3+ cells, mucronulatol exhibited cytotoxicity in the range of 2.7 – 10.2 µg/ml, while no cytotoxic effects were observed in MDR1+ systems at up to 100 µg/ml. Cytometric studies revealed that mucronulatol promoted a global reduction in all cell cycle phases, with a remarkable increase of the apoptotic sub-G1 population. Immunoblotting showed that mucronulatol induced an up-regulation of p21Cip1 and p27Kip1 while down-regulating cyclin E and CDK4 in a drug concentration-dependent manner. No effect on topoisomerase I was observed, while we detected an altered expression of topoisomerases II-α/β. RT-PCR studies showed that 2-fold the IC50 in HCT8 colon carcinoma cells was sufficient for altering the expression pattern of genes in this cell line, including topoisomerase I, thymidilate synthase, EGF receptor and c-myc, amongst others. Conclusion: Here, we demonstrate for the first time that mucronulatol exerts cytotoxicity in cancer cell lines by targeting the control of cell cycle progression, indicating that the mechanism of action of this compound involves interference with the cell cycle machinery.

Author Details

Authors

• D. Díaz-Carballo
• M. Freistühler
• S. Malak
• W. Bardenheuer
• H.P. Reusch

Departments

• ¹ Abteilung Klinische Pharmakologie, Ruhr-Universität Bochum,
• ² Universitätsklinikum Essen, Klinik für Augenheilkunde, Essen and
• ³ Innere Klinik und Poliklinik, Tumorforschung, Universitätsklinikum Essen, Germany

Address

Dr. D. Díaz-Carballo; Abteilung Klinische Pharmakologie, Ruhr-Universität, Bochum, Universitätsstraße 150, 44801 Bochum, Germany
Email: [email protected]

Log in for Subscribers

Citation